Key Points
- Given the good prognosis of low-risk papillary thyroid microcarcinomas
(lrPTMCs) accurate risk stratification is valuable to optimize
management.
- This study aim to evaluate the possible contribution of molecular
testing in the clinical decision-making regarding management of
low-risk papillary thyroid microcarcinomas (lrPTMCs)
- Using a computed decision model, we analyzed the overall benefit
resulting from the treatment strategies for lrPTMCs: active
surveillance (AS) versus hemithyroidectomy (HT), measured by
quality-of-life years (QALYs).
- We found that the optimal strategy that would maximize QALYs, varies
according to BRAFV600E status for patients
without a preset predilection between AS to HT.
- Our model suggests that when there is a dilemma between AS vs. HT for
lrPTMCs, BRAFV600E status can facilitate
decision-making, supporting further real-life studies ofBRAFV600E testing for PTMCs.